Drug intelligence / Profile preview

fulvestrant + trastuzumab

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular, Intravenous, Subcutaneous

Overview

Fulvestrant + trastuzumab is a combination therapy for the treatment of hormone receptor-positive, HER2-positive metastatic breast cancer. Fulvestrant is an estrogen receptor antagonist that degrades the estrogen receptor, while trastuzumab is a monoclonal antibody targeting the HER2/neu (ERBB2) receptor. This combination has shown moderate clinical efficacy and no severe toxicity in patients who have previously received standard anti-HER2 therapy[1]. The primary indication is for advanced or metastatic breast cancer with both hormone receptor and HER2 positivity.

Other names: fulvestrant and trastuzumabtrastuzumab and fulvestrant

Targets

ESR2 (ERβ)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ESR1 (ERα)

Beyond the preview

Go deeper on fulvestrant + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fulvestrant + trastuzumab.

Explore the full profile